Skip to main content
Premium Trial:

Request an Annual Quote

Benitec Announces Positive Animal Data with Lung Cancer Drug Candidate

Premium

Benitec Biopharma last week announced that a collaborator generated preclinical data showing that the company’s expressed RNAi technology can be used to boost survival in a orthotopic mouse model of non-small cell lung cancer.

The work, which was conducted by the Children’s Cancer Institute Australia of the University of South Wales, indicated that animals treated with Benitec’s Tribetarna, which targets the beta III tubulin gene, and chemotherapy survived “significantly” longer than those receiving chemotherapy alone.

After sixty days, 50 percent of the mice treated with Benitec’s drug were alive, versus 14 percent in the chemotherapy-only group.

Benitec said it is currently in discussions with a Ground Zero Pharmaceuticals, a US-based clinical research organization, about initiating discussions with the US Food and Drug Administration to test Tribetarna in humans.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more